Please login to the form below

Not currently logged in


This page shows the latest lasmiditan news and features for those working in and with pharma, biotech and healthcare.

Lilly set to head to regulators with CGRP migraine drug

Lilly set to head to regulators with CGRP migraine drug

Lilly recently added to its galcanezumab programme in migraine by buying CoLucid and its lead drug lasmiditan, an oral serotonin 5-HT 1F agonist that is due to be filed for

Latest news

  • Lilly to buy migraine drug developer CoLucid for $960m Lilly to buy migraine drug developer CoLucid for $960m

    Deal revolves around lasmiditan, which the firm out-licensed in 2005.  . Eli Lilly has agreed a $960m deal to buy CoLucid, claiming rights to a migraine therapy that works in a ... Lasmiditan's different mechanism means it could become the first drug

  • Migraine drugs' headache Migraine drugs' headache

    CoLucid Pharmaceuticals is developing lasmiditan, which specifically agonises the serotonin 1F receptor.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...